Ally Bridge Group and Northpond Ventures, two venture capital firms, agreed to invest $68m in Syapse, a life sciences company. “Ally Bridge is excited to fund Syapse’s highly scalable value-add business that is becoming embedded within leading-edge healthcare systems, and consequential to life science companies based on its ability to deliver real-world evidence and to provide actionable treatment insights, which is exactly where precision medicine is heading,” Frank Yu, Ally Bridge Group Founder, CEO and CIO.